Asco 2025 · Posters · Cáncer de Pulmón Volver

CÁNCER DE PULMÓN

  • Carcinoma pulmonar no microcítico metastásico
Enriqueta Felip, MD, PhD

Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC).

Enriqueta Felip, MD, PhD

Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona.

playAcceso
Guzman Alonso, MD

Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors.

Guzman Alonso, MD

Vall d'Hebron Institute of Oncology (VHIO).

playAcceso
Andrés Aguilar Hernández, Sr., MD

Osimertinib plus repotrectinib phase I trial in TKI-resistant non-small cell lung cancer (NSCLC) with EGFR mutations.

Andrés Aguilar Hernández, Sr., MD

Instituto Oncológico Dr Rosell (IOR), Dexeus University Hospital.

playAcceso
  • Carcinoma pulmonar no microcítico local/regional, microcítico y otros cánceres torácicos
Mercedes Herrera, MD, MSc

Digital spatial profiling for identification of prognostic genes and molecular subgroups in pleural mesothelioma.

Mercedes Herrera, MD, MSc

Hospital Universitario 12 de Octubre, Madrid.

playAcceso
Valentina Gambardella, MD, PhyD

Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation.

Valentina Gambardella, MD, PhyD

Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia.

playAcceso
Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo